Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial discusses the obesity paradox in heart failure, highlighting the epidemiological burden of obesity and its impact on cardiovascular risk factors and heart failure.
This article refers to 'Use of and association between heart failure pharmacological treatments and outcomes in obese versus non-obese patients with heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry' by C. Cappelletto et al., published in this issue on pages 698-710.Obesity is reaching epidemic levels in the United States (US), Europe, and most of the westernized world.In fact, in the US alone, using body mass index (BMI) criteria, 75% of US adults are either overweight or have obesity, and 42% meet criteria for obesity with BMI ≥30 kg/m 2 . 1 Alarmingly, class III or severe obesity (BMI ≥40 kg/m 2 ) is now present in ∼9% of US adults, 1 placing a 'heavy' burden on the US healthcare system.Clearly, obesity has adverse effects on most of the major cardiovascular disease (CVD) risk factors, including increasing levels of blood pressure (BP) and prevalence of hypertension (HTN), raising plasma glucose levels, and increasing the prevalence of metabolic syndrome and diabetes mellitus (DM), increasing dyslipidaemia, especially triglycerides, and lowering high-density lipoprotein cholesterol, and increasing low-grade systemic inflammation.Certainly, HTN and DM are major risk factors for heart failure (HF), and HTN, DM, dyslipidaemia and increased systemic inflammation are risk factors for atherosclerosis and coronary heart disease, which also increase the risk of HF.Additionally, obesity has adverse effects on both systolic and, especially, diastolic ventricular function, also further increasing the risk of HF.Not surprisingly, obesity is a major risk factor for HF, although much more so for HF with preserved ejection fraction (HFpEF) than for HF with reduced ejection fraction (HFrEF), as well as for atrial fibrillation.2,3 The opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Carbone et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: